Abstract
Background Recent studies have advanced our understanding of the genetic drivers of Parkinson’s Disease (PD). Rare variants in more than 20 genes are considered causal for PD, and the latest PD GWAS study identified 90 independent risk loci. However, there remains a gap in our understanding of PD genetics outside of the European populations in which the vast majority of these studies were focused.
Objectives To identify genetic risk factors for PD in a South Asian population.
Methods 674 PD subjects predominantly with age of onset ≤ 50 years (encompassing juvenile, young, or early-onset PD) were recruited from 10 specialty movement disorder centers across India over a 2-year period. 1,376 control subjects were selected from the reference population GenomeAsia, Phase 2. We performed various case-only and case-control genetic analyses for PD diagnosis and age of onset.
Results A genome-wide significant signal for PD diagnosis was identified in the SNCA region, strongly colocalizing with SNCA region signal from European PD GWAS. PD cases with pathogenic mutations in PD genes exhibited, on average, lower PD polygenic risk scores than PD cases lacking any PD gene mutations. Gene burden studies of rare, predicted deleterious variants identified BSN, encoding the presynaptic protein Bassoon that has been previously associated with neurodegenerative disease.
Conclusions This study constitutes the largest genetic investigation of PD in a South Asian population to date. Future work should seek to expand sample numbers in this population to enable improved statistical power to detect PD genes in this understudied group.
Competing Interest Statement
SVA, OBD, MAR, DEL, AGH, GDP, and TS are full-time employees and shareholders of Denali Therapeutics. RM, TSG, SM, MO, SN, AK, PLS, MD, AB, CS, NM, ASP, RG, and VLR are current or former employees of MedGenome Labs.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Vikram Hospital (Bengaluru, India) Private Limited gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Author is deceased.
Relevant conflicts of interest/financial disclosures: SVA, OBD, MAR, DEL, AGH, GDP, and TS are full-time employees and shareholders of Denali Therapeutics. RM, TSG, SM, MO, SN, AK, PLS, MD, AB, CS, NM, ASP, RG, and VLR are current or former employees of MedGenome Labs.
Funding: No funding was received towards this work.
Updated per reviewer feedback and to include new data characterizing the GBA1 p.Ser164Arg variant.
Data Availability
Summary statistics for PD diagnosis GWAS and PD age of onset GWAS are available on Zenodo (https://doi.org/10.5281/zenodo.8436983). Analysis code is also available on Zenodo (https://doi.org/10.5281/zenodo.10011733). Summary statistics for the gene burden analyses are available in the supplementary tables. Access to GAsPh2 data can be obtained through https://browser.genomeasia100k.org/#tid=access. Access to European PD GWAS summary statistics including the 23andme discovery dataset can be obtained through https://research.23andme.com/collaborate/. Chromatin interaction data from CNS cell types can be obtained through https://genome.ucsc.edu/s/nottalexi/glassLab_BrainCellTypes_hg19.
